Summary
Overview
Sean Cole investigates the fascinating and surprisingly rigorous world of pharmaceutical brand naming, exploring why drugs have such unusual names and uncovering the hidden artistry, science, and regulation behind names like Viagra, Prozac, and Lunesta. Through interviews with industry legends like Scott Piergrossi of Brand Institute and Arlene Tech, who named Viagra, the story reveals the complex constraints, creative processes, and even poetry involved in creating drug names that must be distinctive, safe, and memorable in an increasingly crowded marketplace.
The Puzzle of Pharmaceutical Names
The episode opens with the bewildering array of prescription drug names that sound like scrambled words or sci-fi villains. Sean Cole sets out to answer the Seinfeldian question of what's the deal with these names, promising to reveal not just logic but actual poetry behind the seemingly nonsensical naming conventions. The investigation aims to uncover why drugs can't simply have easy, approachable names and how the industry arrived at names that sound like Star Trek characters.
- Pharmaceutical brand names sound strange and disorienting, like watching TV after having a partial stroke
- The question is whether the unusual names are by design, necessary, or simply wrongheaded marketing
- Underneath the noisiness is not just logic but actual poetry that most people never imagine
" It's like watching TV in the middle of the day can make you feel like you've had a partial stroke that scrambled half the words on the screen, which is ironic considering that that's probably what some of the drugs they're advertising are supposed to prevent. "
Inside Brand Institute: The Pharmaceutical Naming Powerhouse
Scott Piergrossi of Brand Institute reveals that his company names over 75% of new drugs on the market each year. The process is far more rigorous than most people imagine, starting with teams generating 300-500 initial name ideas and whittling them down through multiple rounds of client feedback. Despite asking for simple, easy-to-pronounce names, clients often reject them because they can't envision them as their product, making the process both systematic and subjective.
- Brand Institute names more than 75% of new drugs on the market in a given year
- The naming process starts with teams generating 300-500 initial ideas that get narrowed down
- Clients often ask for easy-to-pronounce names but reject them because they can't see them as their product
- The process is the opposite of the spontaneous approach shown in comedy sketches - it's methodical and time-consuming
" Clients will say, just give me an easy to pronounce name and we'll call this a win. And then we present a slide, let's say, of 25. And we'll be lucky if we get to retain two of them. They are all solely easy to pronounce. And the client is just like, nah, I just don't like it. And I'm like, but that's what you asked for. "
📚 6 more sections below
Sign up to unlock the complete summary with all insights, key points, and quotes
Get this summary + all future 99% Invisible episodes in your inbox
100% Free • Unsubscribe Anytime
Sign up now and we'll send you the complete summary of this episode, plus get notified when new 99% Invisible episodes are released—delivered straight to your inbox within minutes.